XML 27 R17.htm IDEA: XBRL DOCUMENT
v3.22.2

BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES (Tables) | 9 Months Ended
--- | ---
Jun. 30, 2022
BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES |
Schedule of operations and timing of revenue recognition | The following table presents revenues disaggregated by our business operations and timing of revenue recognition: ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Month Period Ended:
​ | ​ | June 30, | ​ | June 30,
​ |  | 2022 |  | 2021
Research and development services (over-time) | ​ | $ | 152,732 | ​ | $ | 197,812
Clinical laboratory testing services (point-in-time) | ​ | ​ | 2,506,976 | ​ | ​ | 695,213
Clinical laboratory testing services (over-time) | ​ | ​ | 1,386,834 | ​ | ​ | 131,400
Product and authentication services (point-in-time): | ​ |  | ​ | ​ |  | ​
Supply chain | ​ |  | 43,243 | ​ |  | 23,947
Asset marking | ​ |  | 127,075 | ​ |  | 113,721
Diagnostic test kits and supplies | ​ | ​ | 79,511 | ​ | ​ | 538,227
Total | ​ | $ | 4,296,371 | ​ | $ | 1,700,320
​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Nine Month Period Ended:
​ | ​ | June 30, | ​ | June 30,
​ |  | 2022 |  | 2021
Research and development services (over-time) | ​ | $ | 472,539 | ​ | $ | 586,285
Clinical laboratory testing services (point-in-time) | ​ |  | 8,712,565 | ​ |  | 2,698,463
Clinical laboratory testing services (over-time) | ​ |  | 3,871,609 | ​ |  | 455,800
Product and authentication services (point-in-time): | ​ |  | ​ | ​ |  | ​
Supply chain | ​ |  | 570,252 | ​ |  | 123,947
Asset marking | ​ |  | 380,039 | ​ |  | 386,160
Diagnostic test kits and supplies | ​ |  | 602,356 | ​ |  | 1,737,348
Total | ​ | $ | 14,609,360 | ​ | $ | 5,988,003
Schedule of opening and closing contract balances | The opening and closing balances of the Company’s contract balances are as follows: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | October 1, | ​ | June 30, | ​ | $
​ |  | Balance sheet classification |  | 2021 |  | 2022 |  | change
Contract liabilities |  | Deferred revenue | ​ | $ | 281,000 | ​ | $ | 757,264 | ​ | $ | 476,264
​
Schedule of anti-dilutive securities not included computation of net loss per share | ​
​ | ​ | ​ | ​ | ​
​ |  | 2022 |  | 2021
Warrants |  | 2,239,963 |  | 745,268
Stock options |  | 1,063,143 |  | 452,485
Total |  | 3,303,106 |  | 1,197,753

X
- References No definition available. + Details
Name: | us-gaap_AccountingPoliciesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 10 -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045 + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257 + Details
Name: | us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration